Rethinking Guideline Delivery in Nephrology: From Access to Action - Kidney International Reports www.kireports.org/article/S246...
See #NephJC and @freelyfiltered.bsky.social contribution to guideline dissemination
@kireports.bsky.social from @kidneyboy.bsky.social et al
See #NephJC and @freelyfiltered.bsky.social contribution to guideline dissemination
@kireports.bsky.social from @kidneyboy.bsky.social et al
October 14, 2026 at 4:05 PM
Rethinking Guideline Delivery in Nephrology: From Access to Action - Kidney International Reports www.kireports.org/article/S246...
See #NephJC and @freelyfiltered.bsky.social contribution to guideline dissemination
@kireports.bsky.social from @kidneyboy.bsky.social et al
See #NephJC and @freelyfiltered.bsky.social contribution to guideline dissemination
@kireports.bsky.social from @kidneyboy.bsky.social et al
10/10
Final thoughts:
Transplant benefits are certainly not universal and require careful conversations about individualized benefits.
Up next- ASN #KidneyWeek26 in Denver, CO. Hope to see you there! Check out NephJC.com, become a donor and for party details.
Final thoughts:
Transplant benefits are certainly not universal and require careful conversations about individualized benefits.
Up next- ASN #KidneyWeek26 in Denver, CO. Hope to see you there! Check out NephJC.com, become a donor and for party details.
NephJC
NephJC.com
October 14, 2026 at 1:00 AM
10/10
Final thoughts:
Transplant benefits are certainly not universal and require careful conversations about individualized benefits.
Up next- ASN #KidneyWeek26 in Denver, CO. Hope to see you there! Check out NephJC.com, become a donor and for party details.
Final thoughts:
Transplant benefits are certainly not universal and require careful conversations about individualized benefits.
Up next- ASN #KidneyWeek26 in Denver, CO. Hope to see you there! Check out NephJC.com, become a donor and for party details.
9/10
I want more info:
link to the NephJC blog and VAs
www.nephjc.com/news/transpl...
Urvashi
SM Assad
Daniel
I want more info:
link to the NephJC blog and VAs
www.nephjc.com/news/transpl...
Urvashi
SM Assad
Daniel
Can Dialysis Outshine Transplant in the Elderly? — NephJC
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and don...
www.nephjc.com
October 14, 2026 at 1:00 AM
9/10
I want more info:
link to the NephJC blog and VAs
www.nephjc.com/news/transpl...
Urvashi
SM Assad
Daniel
I want more info:
link to the NephJC blog and VAs
www.nephjc.com/news/transpl...
Urvashi
SM Assad
Daniel
8/10
#NephJC Consensus:
In most cases, DDKT can improve survival compared to continued dialysis.
Not all donor kidneys are created equal (SCD, ECD, DCD, DBD).
Discussion of recipient and donor quality should be undertaken during transplant evaluation, as well of goals of care
#NephJC Consensus:
In most cases, DDKT can improve survival compared to continued dialysis.
Not all donor kidneys are created equal (SCD, ECD, DCD, DBD).
Discussion of recipient and donor quality should be undertaken during transplant evaluation, as well of goals of care
October 14, 2026 at 1:00 AM
8/10
#NephJC Consensus:
In most cases, DDKT can improve survival compared to continued dialysis.
Not all donor kidneys are created equal (SCD, ECD, DCD, DBD).
Discussion of recipient and donor quality should be undertaken during transplant evaluation, as well of goals of care
#NephJC Consensus:
In most cases, DDKT can improve survival compared to continued dialysis.
Not all donor kidneys are created equal (SCD, ECD, DCD, DBD).
Discussion of recipient and donor quality should be undertaken during transplant evaluation, as well of goals of care
1/10
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
October 14, 2026 at 1:00 AM
1/10
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
Do older pts benefit from kidney transplant?🤔
Does donor quality change the equation?👀
Check out this week's #NephJC summary! #NephSky
Does donor quality change the equation?👀
Check out this week's #NephJC summary! #NephSky
This week we are looking at a target trial emulation on transplantation.
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
Can Dialysis Outshine Transplant in the Elderly? — NephJC
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and don...
www.nephjc.com
October 13, 2026 at 3:06 AM
TARGET trial: El Resumen Visual
Gracias @danyrcal.bsky.social y @dramiliflores.bsky.social
www.nephjc.com/news/target2
Gracias @danyrcal.bsky.social y @dramiliflores.bsky.social
www.nephjc.com/news/target2
TARGET trial: El Resumen Visual — NephJC
¿El trasplante renal de donante fallecido siempre ofrece mayores ventajas que continuar en diálisis?
www.nephjc.com
October 12, 2026 at 2:36 PM
TARGET trial: El Resumen Visual
Gracias @danyrcal.bsky.social y @dramiliflores.bsky.social
www.nephjc.com/news/target2
Gracias @danyrcal.bsky.social y @dramiliflores.bsky.social
www.nephjc.com/news/target2
Check out the VA by @danyrcal
Do older, sicker patients benefit from kidney transplantation?
This is a nuanced "it depends" answer that is worthy of discussion. #NephSky #NephJC
www.nephjc.com/news/targetva
Do older, sicker patients benefit from kidney transplantation?
This is a nuanced "it depends" answer that is worthy of discussion. #NephSky #NephJC
www.nephjc.com/news/targetva
TARGET TRIAL: The Visual Abstract — NephJC
Can a deceased donor kidney transplant offer better survival than continuing dialysis in elderly?
www.nephjc.com
October 12, 2026 at 2:34 PM
Check out the VA by @danyrcal
Do older, sicker patients benefit from kidney transplantation?
This is a nuanced "it depends" answer that is worthy of discussion. #NephSky #NephJC
www.nephjc.com/news/targetva
Do older, sicker patients benefit from kidney transplantation?
This is a nuanced "it depends" answer that is worthy of discussion. #NephSky #NephJC
www.nephjc.com/news/targetva
This week we are looking at a target trial emulation on transplantation.
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
Can Dialysis Outshine Transplant in the Elderly? — NephJC
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and don...
www.nephjc.com
October 12, 2026 at 2:29 PM
This week we are looking at a target trial emulation on transplantation.
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
12 years of #NephJC. Countless papers discussed, ideas challenged, and friendships made.
🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
www.nephjc.com/news/2026/9/...
🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
www.nephjc.com/news/2026/9/...
NephJC 2026 Fall Pledge Drive — NephJC
Help keep NephJC a vital, original, and unbiased source of medical education.
www.nephjc.com
October 9, 2026 at 5:59 PM
12 years of #NephJC. Countless papers discussed, ideas challenged, and friendships made.
🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
www.nephjc.com/news/2026/9/...
🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
www.nephjc.com/news/2026/9/...
Finally the results of Prepare for Kidney Care are coming! What an achievement to complete this trial - can't wait to see what they found! One for Nephjc perhaps? @theisn.org @nephjc.bsky.social
For the first time, we have randomized trial evidence comparing preparation for dialysis with conservative kidney management in older people approaching kidney failure.
📅 Nov 5: Discover the first results of the Prepare for Kidney Care trial in an ISN webinar.
🔗 Register: https://bit.ly/4hykcWw
📅 Nov 5: Discover the first results of the Prepare for Kidney Care trial in an ISN webinar.
🔗 Register: https://bit.ly/4hykcWw
October 9, 2026 at 7:55 AM
Finally the results of Prepare for Kidney Care are coming! What an achievement to complete this trial - can't wait to see what they found! One for Nephjc perhaps? @theisn.org @nephjc.bsky.social
Can an oral small molecule provide renal and cardiovascular benefits just like the injectable GLP1 meds? The answer is probably so! New blog post today about Achieve 4 and it's CV trial that was presented at EASD. They also looked at it's renal benefits. So shout-out to #NephJC as well.
Clearing the CVOT hurdle
O
the-incretins.beehiiv.com
October 7, 2026 at 5:03 PM
Can an oral small molecule provide renal and cardiovascular benefits just like the injectable GLP1 meds? The answer is probably so! New blog post today about Achieve 4 and it's CV trial that was presented at EASD. They also looked at it's renal benefits. So shout-out to #NephJC as well.
Select RCTs, informing current management strategies for patients with SA-AKI
#Nephpearls #AKIinICU #NephJC #NephSky
👉 shop.lww.com/Handbook-of-...
#Nephpearls #AKIinICU #NephJC #NephSky
👉 shop.lww.com/Handbook-of-...
October 4, 2026 at 5:58 PM
Select RCTs, informing current management strategies for patients with SA-AKI
#Nephpearls #AKIinICU #NephJC #NephSky
👉 shop.lww.com/Handbook-of-...
#Nephpearls #AKIinICU #NephJC #NephSky
👉 shop.lww.com/Handbook-of-...
4/ Potassium gradients drive arrhythmia. Continuous monitoring shows AV/VAs cluster around dialysis. But current studies are small, crossover, and underpowered
www.nephjc.com/news/potassi...
www.nephjc.com/news/potassi...
Potassium Rollercoaster Heartbreak — NephJC
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythm...
www.nephjc.com
October 3, 2026 at 9:23 PM
4/ Potassium gradients drive arrhythmia. Continuous monitoring shows AV/VAs cluster around dialysis. But current studies are small, crossover, and underpowered
www.nephjc.com/news/potassi...
www.nephjc.com/news/potassi...
Can tolvaptan keep up with 3% saline?
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
www.nephjc.com/news/tolvapt...
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
www.nephjc.com/news/tolvapt...
Raising sodium: can tolvaptan rival 3% hypertonic saline? — NephJC
Testing Tolvaptan versus 3% saline and the rate of rise of serum sodium in healthy volunteers.
www.nephjc.com
October 3, 2026 at 7:39 PM
Can tolvaptan keep up with 3% saline?
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
www.nephjc.com/news/tolvapt...
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
www.nephjc.com/news/tolvapt...
Freely Filtered, a NephJC Podcast
FF97 MERCURI-2, Can a Flozin prevent AKI?
Freely Filtered, a NephJC Podcast · Episode
open.spotify.com
September 30, 2026 at 12:27 PM
Freely Filtered, a NephJC Podcast
11/10 ➡️Up next on 10/13: Survival benefit of deceased donor kidney transplantation versus continued dialysis: international target trial emulation | The BMJ
www.bmj.com/content/394/...
Join us www.nephjc.com/
www.bmj.com/content/394/...
Join us www.nephjc.com/
NephJC
www.nephjc.com
September 30, 2026 at 1:27 AM
11/10 ➡️Up next on 10/13: Survival benefit of deceased donor kidney transplantation versus continued dialysis: international target trial emulation | The BMJ
www.bmj.com/content/394/...
Join us www.nephjc.com/
www.bmj.com/content/394/...
Join us www.nephjc.com/
9/10 I want more info:
nephjc.com/news/startst...
www.nephjc.com/news/starttr...
www.nephjc.com/news/startsp...
Andreea Manolea,
Farah Wehbe,
David White
nephjc.com/news/startst...
www.nephjc.com/news/starttr...
www.nephjc.com/news/startsp...
Andreea Manolea,
Farah Wehbe,
David White
Why Can’t I Quit You: Steroid Tapering in Adults with Podocytopathies (START) — NephJC
This week, we will discuss the best schedule for tapering steroids in adult patients with podocytopathies (MCD/FSGS).
nephjc.com
September 30, 2026 at 1:27 AM
9/10 I want more info:
nephjc.com/news/startst...
www.nephjc.com/news/starttr...
www.nephjc.com/news/startsp...
Andreea Manolea,
Farah Wehbe,
David White
nephjc.com/news/startst...
www.nephjc.com/news/starttr...
www.nephjc.com/news/startsp...
Andreea Manolea,
Farah Wehbe,
David White
8/10 ⚠️ #NephJC Consensus
💡Underpowered (94/114 target, ~75% power), open-label, 2 center trial, wide margin (CI compatible w/ ~14 extra relapses/100 pts short-course), and FSGS trended toward favoring the longer taper underpowered subgroup
💡Hypothesis-generating only
💡Underpowered (94/114 target, ~75% power), open-label, 2 center trial, wide margin (CI compatible w/ ~14 extra relapses/100 pts short-course), and FSGS trended toward favoring the longer taper underpowered subgroup
💡Hypothesis-generating only
September 30, 2026 at 1:27 AM
8/10 ⚠️ #NephJC Consensus
💡Underpowered (94/114 target, ~75% power), open-label, 2 center trial, wide margin (CI compatible w/ ~14 extra relapses/100 pts short-course), and FSGS trended toward favoring the longer taper underpowered subgroup
💡Hypothesis-generating only
💡Underpowered (94/114 target, ~75% power), open-label, 2 center trial, wide margin (CI compatible w/ ~14 extra relapses/100 pts short-course), and FSGS trended toward favoring the longer taper underpowered subgroup
💡Hypothesis-generating only
7/10
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
September 30, 2026 at 1:27 AM
7/10
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
6/10
Question 1
#NephJC #Nephsky or #NephTwitter
Q: Should we stop steroids quickly in all podocytopathies?
A: Probably not, but this gives us evidence that we should explore this further in larger trial, as less steroids has less AE exposure, but also without more relapses
Question 1
#NephJC #Nephsky or #NephTwitter
Q: Should we stop steroids quickly in all podocytopathies?
A: Probably not, but this gives us evidence that we should explore this further in larger trial, as less steroids has less AE exposure, but also without more relapses
September 30, 2026 at 1:27 AM
6/10
Question 1
#NephJC #Nephsky or #NephTwitter
Q: Should we stop steroids quickly in all podocytopathies?
A: Probably not, but this gives us evidence that we should explore this further in larger trial, as less steroids has less AE exposure, but also without more relapses
Question 1
#NephJC #Nephsky or #NephTwitter
Q: Should we stop steroids quickly in all podocytopathies?
A: Probably not, but this gives us evidence that we should explore this further in larger trial, as less steroids has less AE exposure, but also without more relapses
1/10 #NephJC #TenPosts #NephSly
🫘💊 START your steroids! A question we ask constantly but adult RCT data rarely answers after remission in steroid-sensitive MCD/FSGS, how long should the prednisolone taper actually be? 🧵
www.sciencedirect.com/science/arti...
🫘💊 START your steroids! A question we ask constantly but adult RCT data rarely answers after remission in steroid-sensitive MCD/FSGS, how long should the prednisolone taper actually be? 🧵
www.sciencedirect.com/science/arti...
www.sciencedirect.com
September 30, 2026 at 1:27 AM
1/10 #NephJC #TenPosts #NephSly
🫘💊 START your steroids! A question we ask constantly but adult RCT data rarely answers after remission in steroid-sensitive MCD/FSGS, how long should the prednisolone taper actually be? 🧵
www.sciencedirect.com/science/arti...
🫘💊 START your steroids! A question we ask constantly but adult RCT data rarely answers after remission in steroid-sensitive MCD/FSGS, how long should the prednisolone taper actually be? 🧵
www.sciencedirect.com/science/arti...
📢 The New #NephJC VA just dropped in !!!
@kireports.bsky.social
It's a study from @PGINEPHRO and I am a co-author🤩
Thanks to Dr. Raja Ramachandran, Dr. Arun
After obtaining remission, 2 months is non inferior to standard 4 months steroid tapering in podocytopathy.
#Nephbluesky #Nephsky #NephEd
@kireports.bsky.social
It's a study from @PGINEPHRO and I am a co-author🤩
Thanks to Dr. Raja Ramachandran, Dr. Arun
After obtaining remission, 2 months is non inferior to standard 4 months steroid tapering in podocytopathy.
#Nephbluesky #Nephsky #NephEd
Hey #NephJC 👋
Checkout the VA by @divyaveerssneph.bsky.social
This week we're looking at steroid weaning strategies in adults with podocytopathies (MCD/FSGS).
💊Steroids: easy to start🟢 but hard to stop 🛑.
#NephSky
www.nephjc.com/news/starttrial
Checkout the VA by @divyaveerssneph.bsky.social
This week we're looking at steroid weaning strategies in adults with podocytopathies (MCD/FSGS).
💊Steroids: easy to start🟢 but hard to stop 🛑.
#NephSky
www.nephjc.com/news/starttrial
START: The Visual Abstract — NephJC
Can steroid tapering be shorter after remission in adults with sensitive podocytopathy?
www.nephjc.com
September 28, 2026 at 3:38 PM
📢 The New #NephJC VA just dropped in !!!
@kireports.bsky.social
It's a study from @PGINEPHRO and I am a co-author🤩
Thanks to Dr. Raja Ramachandran, Dr. Arun
After obtaining remission, 2 months is non inferior to standard 4 months steroid tapering in podocytopathy.
#Nephbluesky #Nephsky #NephEd
@kireports.bsky.social
It's a study from @PGINEPHRO and I am a co-author🤩
Thanks to Dr. Raja Ramachandran, Dr. Arun
After obtaining remission, 2 months is non inferior to standard 4 months steroid tapering in podocytopathy.
#Nephbluesky #Nephsky #NephEd